Brief: Jazz Pharmaceuticals Q4 Adjusted EPS USD 6.64 Vs. IBES Estimate USD 6.52
24/02/2026 21:05
Feb 24 (Reuters) - Jazz Pharmaceuticals Q4 revenue USD 1,197.926 million vs. IBES estimate USD 1,165 million. Q4 adjusted net income USD 420.888 million vs. IBES estimate USD 405.9 million Q4 net income USD 203.451 million Q4 EPS USD 3.21 outlook FY revenue USD 4,250-4,500 million
Recent news on Jazz Pharmaceuticals
See all newsBrief: Jazz Pharmaceuticals Enters Amendment No. 4 To Credit Agreement On Sept 23, 2026
U.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Jazz Pharma dips after upsized $1.1 bln convertible offering
Brief: Jazz Pharmaceuticals Announces Private Offering Of $1.0 Billion Of Exchangeable Senior Notes Due 2032